Announced
Completed
Synopsis
Avista-backed Acino, a Swiss pharmaceutical company, completed the acquisition of the drug portfolio of Takeda Pharmaceutical in EMEA, a global, R&D-driven biopharmaceutical firm, for $200m. This is the third transaction in FY19 that furthers Takeda’s strategy to focus on business areas core to its long-term growth and facilitate rapid deleveraging following its acquisition of Shire. “The divestment of non-core assets sold in NEMEA represents the continued execution of our strategy to optimize our portfolio, invest in the defined core business areas, and accelerate our progress toward reaching our target leverage ratio,” Costa Saroukos, Takeda Chief Financial Officer.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.